With the addition of peptides such as BPC-157 and decompression therapy to our treatment offerings, we can offer a more comprehensive approach to healing and recovery
BPC/TB-15 is administered via subcutaneous injection 2-3 times per week, similar to the standard dose but with a more concentrated formulation
The regulatory status factor An important consideration that affects the risk calculus: cagrilintide is not currently FDA-approved as a standalone medication
A large proportion of children diagnosed with ASD manifest additional symptoms including cognitive deficits, developmental delay, anxiety and other medical comorbidities with mood and psychiatric disorders [1, 2]
Ulatowski LM, Manor D
Sikiri, P., Rotkvi, I., Mie, S., Krianac, ., Gjuri, V., Juki, J., & Ani, T